Guardant Health, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
40131M109
SEDOL
BFXC911
CIK
0001576280
guardanthealth.com
LEI:
©
FIGI: BBG006D97VY9
GH
Guardant Health, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Diagnostics & Research
AI
PROFILER
NAME
Guardant Health, Inc.
ISIN
US40131M1099
TICKER
GH
MIC
XNAS
REUTERS
GH.OQ
BLOOMBERG
GH US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Fri, 20.12.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network. ...
Read More
Guardant Health
Technical Analysis Termsheet Terminal
Permalink
Thu, 19.12.2024       Guardant Health
US40131M1099

COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care c...
Read More
Guardant Health
Technical Analysis Termsheet Terminal
Permalink
Wed, 18.12.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selective...
Read More
Guardant Health
Technical Analysis Termsheet Terminal
Permalink
Mon, 09.12.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data demonstrating the benefits of its precision oncology tests, real-world clinical-genomic database and AI analytics in optimizing therapy selection, identifying resistance mutations, and predicting lo...
Read More
Guardant Health
Technical Analysis Termsheet Terminal
Permalink
Wed, 13.11.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 233,603 shares of its common stock to 123 new non-executive employees and non-qualified stock option aw...
Read More
Guardant Health
Technical Analysis Termsheet Terminal
Permalink
Wed, 06.11.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Recorded revenue of $191.5 million for the third quarter of 2024, an increase of 34% over the third quarter of 2023 Reported 53,100 clinical tests (excludi...
Read More
Guardant Health
Technical Analysis Termsheet Terminal
Permalink
Fri, 01.11.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. ●   Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA     Fireside chat on Tuesday, November 12 at 10:30 a.m. Eastern Time       ●   ...
Read More
Guardant Health
Technical Analysis Termsheet Terminal
Permalink
Wed, 30.10.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the inclusion of its blood-based colorectal cancer screening product Shield in TIME’s annual list of the Best Inventions, which features 200 extraordinary innovations changing lives. To compile this year's list, TIME solicited nominations from TIME editors a...
Read More
Guardant Health
Technical Analysis Termsheet Terminal
Permalink
Mon, 28.10.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data supporting the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening adherence at the American College of Gastroenterology (ACG) 2024 Annual Meeting in Philade...
Read More
Guardant Health
Technical Analysis Termsheet Terminal
Permalink
Thu, 24.10.2024       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. “We a...
Read More
Guardant Health
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S